Beta Bionics is excited to announce a significant milestone in its journey to revolutionize diabetes management with the recent successful funding round of $234.6 million. As a commercial stage medical technology company committed to transforming the lives of insulin-requiring people with diabetes (PWDs), this capital injection reinforces our mission to innovate and deliver advanced solutions that simplify treatment and improve overall quality of life. Our flagship product, the iLet Bionic Pancreas, stands as the first FDA-cleared autonomous insulin delivery device on the market鈥攁 testament to years of rigorous research, development, and testing. By harnessing advanced adaptive algorithms, the iLet Bionic Pancreas tailors insulin delivery in real time, ensuring a seamless and efficient therapeutic experience for PWDs. This funding will primarily be allocated to accelerating our research and development efforts, expanding our commercial footprint, and further enhancing our technology to meet the diverse needs of patients worldwide. Additionally, we plan on investing in broader educational initiatives and patient support programs designed to empower individuals through information and dedicated resources. As we build on our legacy of innovation in medical technology, our community of healthcare professionals, patients, and partners remains at the forefront of our strategic vision. To learn more about our revolutionary approach to diabetes care and ongoing projects, please visit www.betabionics.com. For safety information regarding our devices, we invite you to visit www.betabionics.com/safety. With this new funding, Beta Bionics is poised to change the landscape of diabetes management and enhance the everyday lives of countless individuals.
Beta Bionics Secures $234.6M to Accelerate Next-Generation Autonomous Insulin Delivery Innovations
Recently funded 路 $234.6MHealthcare
Get the full Beta Bionics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
